NWPharmaTech CHR-P Research Programme

DeSci infrastructure for regulated clinical development

A new capital layer for early-intervention psychiatry.

NWPharmaTech is exploring a ring-fenced programme-financing model for its CHR-P development programme, combining regulated private capital, milestone accountability and digital transparency while preserving conventional pharmaceutical governance.

  • Private route under evaluation
  • ~US$10m planning target
  • No public token offering
Request a programme-financing conversation Explore how it could work

Exploratory programme architecture. Not an offer or solicitation.

  • NWPT-SM32300 is investigational.
  • Effectiveness in CHR-P is not established.
  • The proposed next study is not recruiting.
  • Prevention is not the current primary aim of the proposed next study.

Decentralised capital. Centralised clinical responsibility.

Capital can be distributed. Clinical accountability cannot.

How a ring-fenced structure could move capital toward a defined clinical step, with NWPharmaTech inside a protected sponsor boundary. The structure is under evaluation; nothing on this path is live.

  • Capital and controls
  • Sponsor boundary
  • Reporting and outcome
  1. 01

    Qualified private capital

    Eligible investors and partners, through private conversations only. Nothing is raised on this website.

  2. 02

    Ring-fenced programme vehicle

    A proposed vehicle limited to expressly granted CHR-P programme economics.

  3. 03

    Milestone-controlled treasury

    Bank or custody accounts with dual-control release against operational milestones, not efficacy claims.

  4. Sponsor boundary

    1. 04

      NWPharmaTech — sponsor

      Remains the pharmaceutical sponsor: protocol, dose, endpoints, safety, CMC, regulatory filings and core IP.

    2. 05

      Clinical / CMC / regulatory execution

      Preparation and start-up work toward the proposed Phase 2B, subject to financing and approvals.

  5. 06

    Verified programme reporting

    Progress and use of funds reported against agreed operational milestones. The verification method is part of the structure under evaluation.

  6. 07

    Next clinical value inflection

    Readiness for the proposed Phase 2B: an operational step, not an efficacy or prevention result.

Architecture

Three layers. One protected clinical core.

Capital layer

Who could finance the programme

  • Private investors
  • Strategic capital
  • Impact capital
  • Potential digital rails
  • Milestone-linked capital deployment

Transparency layer

How progress could be followed

  • Programme reporting
  • Milestone verification
  • Use-of-funds visibility
  • Permissioned digital records
  • Potential on-chain provenance

Sponsor layer · protected clinical boundary

NWPharmaTech retains

  • Protocol
  • Dose
  • Endpoints
  • Safety
  • CMC
  • Regulatory submissions
  • IP
  • Licensing
  • Eligibility criteria remain within the sponsor-approved protocol. Individual participant eligibility is determined by investigators/sites under the protocol and applicable oversight.

Investigators, ethics committees and regulators remain independent.

The line we hold

What gets decentralised, and what does not.

Can be distributed

  • Capital formation
  • Investor participation
  • Reporting
  • Milestone verification
  • Research-community engagement
  • Potential digital record keeping

Stays with the sponsor

  • Clinical protocol
  • Dose selection
  • Endpoints
  • Safety decisions
  • Medical and safety oversightIndependent committees and ethics bodies stay independent.
  • CMC release
  • Regulatory strategy
  • IP
  • Licensing
  • Eligibility criteria remain within the sponsor-approved protocol. Individual participant eligibility is determined by investigators/sites under the protocol and applicable oversight.

Blockchain should record accountability, not practice medicine.

Capital supporters do not vote on clinical design, trial budget or sponsor decisions. Transparent financing does not mean decentralised clinical governance.

Process

How a private financing could work.

  1. 01

    Conversation

    A qualified investor or partner begins a private discussion.

  2. 02

    Diligence

    Science, programme, use of funds and proposed structure are reviewed.

  3. 03

    Structure

    The legal instrument and programme-specific contractual rights are defined privately.

  4. 04

    Eligibility

    Applicable KYC, investor and jurisdiction checks are completed.

  5. 05

    Close

    A conventional private closing; a permissioned digital record may be added where feasible.

  6. 06

    Report

    Capital deployment and programme progress are reported against agreed milestones.

Instrument, economic rights, jurisdictions and digital-record architecture remain under evaluation. Conventional register-first private placement remains available as the fallback.

The next financing objective

~US$10mCurrent planning target for catalytic preparation and start-up toward the proposed Phase 2B programme.

  • Clinical start-up

    Synopsis and protocol path, CRO selection and study start-up.

  • Site activation

    First-site readiness when approvals allow. No one is being recruited.

  • CMC / supply

    Investigational product readiness for a start window.

  • Regulatory execution

    Ethics and regulatory start-up work.

  • Programme operations

    Programme management, contingency and controlled wind-down capacity.

  • Evidence infrastructure

    Data management, analysis planning and programme reporting.

Not presented as the full cost of global Phase 2B. A bottoms-up RFQ and use-of-proceeds exercise is being developed. The target is a planning assumption, not a Board-approved budget.

Explore funding use

Why digital rails?

Infrastructure for accountability, under evaluation.

  • Provenance

    Durable records of programme milestones and reporting.

  • Accountability

    Potential milestone-linked controls around capital deployment.

  • Coordination

    Enable different categories of sophisticated capital to participate around one programme.

  • Transparency

    Make progress easier to follow without disclosing confidential patient, regulatory or IP information.

  • Programmability

    Potential automation of permitted administrative and reporting functions while clinical decisions remain off-chain.

Programme status

Where things stand.

CHR-P programmeAs stated on this website · last reviewed 30 September 2026
Programme
CHR-P
Candidate
NWPT-SM32300 investigational
Status
Proposed next clinical study
Effectiveness
Not established
Recruiting
No
Prevention as primary aim
No not the current primary aim of the proposed study
Programme financing
Private conversations
Structure
Under evaluation
Planning target
~US$10m catalytic preparation and start-up
Public token
None
Wallet / payment
Not enabled
Clinical governance
NWPharmaTech

Plain answers

What this is, and what it is not.

Can I invest, buy a token or connect a wallet here?

No. There is no live public offering, no public token sale, no token allocation, no payment rail, no minting and no staking on this website. You cannot invest, pay or connect a wallet here.

Are any returns, liquidity or price movements promised?

No. Nothing here promises liquidity, appreciation, interest, APY or any yield, and there is no price chart. Any future economic rights would exist only under appropriate definitive private documentation, eligibility checks and applicable law.

Does ~US$10m fund the Phase 2B study?

No. Approximately US$10m is the current planning target for catalytic preparation and start-up toward the proposed Phase 2B. It is not presented as the full cost of Phase 2B; the detailed RFQ and bottoms-up use-of-proceeds exercise is still in development.

Would financiers or tokenholders influence the trial?

No. There is no tokenholder clinical governance. NWPharmaTech keeps sponsor authority over protocol, dose, endpoints, safety, CMC, manufacturing, regulatory submissions, IP and licensing or commercial decisions. Eligibility criteria remain within the sponsor-approved protocol. Individual participant eligibility is determined by investigators/sites under the protocol and applicable oversight.

What would a digital record be for?

A permissioned digital record at close is being evaluated where it is legally and operationally useful: to record accountability and reporting, not to make clinical decisions. If it is not feasible, a conventional register-first private placement remains the fallback.

Is there a data room?

No public data room. Diligence materials, where appropriate, are shared privately after a conversation.

Explore the programme

Science, capital and documentation, in one place.

Fund the next honest step — not a finished cure.

The purpose of programme financing is to fund a clearly defined next clinical step while making uncertainty, accountability and sponsor responsibility explicit.

Request a programme-financing conversation Explore the evidence

Exploratory information only. No investment, token or allocation is being offered through this website.

Last reviewed: 30 September 2026